Literature DB >> 22193879

Orbitofacial neurofibromatosis: clinical characteristics and treatment outcome.

I A Chaudhry1, J Morales, F A Shamsi, W Al-Rashed, E Elzaridi, Y O Arat, C Jacquemin, D T Oystreck, T M Bosley.   

Abstract

PURPOSE: To report clinical observations and surgical management in a large series of patients with orbitofacial neurofibromatosis type 1 (OFNF). PATIENTS AND METHODS: Patients were identified and medical records reviewed for demographic data, ophthalmologic examinations, surgical interventions, and procedure outcome to create a retrospective, non-comparative case series of patients with OFNF seen at one medical centre over a 23-year period.
RESULTS: Sixty patients with OFNF (31 females and 29 males; mean age, 14 years) were followed for an average of 5.7 years. Presenting signs and symptoms included eyelid swelling in all patients, ptosis in 56 (93.3%), proptosis in 34 (56.6%), dystopia or strabismus in 30 (50%), and decreased visual acuity in 50 (83.3%). Surgical intervention included ptosis repair in 54 (90%; mean 1.6 surgical procedures), facial and orbital tumour debulking in 54 (90%; mean 2.3 surgeries), and canthoplasty in 28 (46.6%) patients. Eleven patients required enucleation or exenteration of a blind eye.
CONCLUSION: Patients with OFNF often require multiple procedures to preserve vision, prevent additional disfigurement, and achieve cosmetic rehabilitation. Patients need regular ophthalmological monitoring given the potential for progressive visual and cosmetic consequences.

Entities:  

Mesh:

Year:  2011        PMID: 22193879      PMCID: PMC3325560          DOI: 10.1038/eye.2011.336

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  25 in total

Review 1.  Management of craniofacial neurofibromatosis.

Authors:  I T Jackson
Journal:  Facial Plast Surg Clin North Am       Date:  2001-02       Impact factor: 1.918

2.  Screening children with NF1 for optic pathway glioma--Yes.

Authors:  I Simmons; D Gogi
Journal:  Eye (Lond)       Date:  2010-06-25       Impact factor: 3.775

3.  Buphthalmos in neurofibromatosis: is it an expression of regional giantism?

Authors:  C S Hoyt; F A Billson
Journal:  J Pediatr Ophthalmol       Date:  1977 Jul-Aug

4.  Reassessment of sphenoid dysplasia associated with neurofibromatosis type 1.

Authors:  Claude Jacquemin; Thomas M Bosley; Don Liu; Helena Svedberg; Amal Buhaliqa
Journal:  AJNR Am J Neuroradiol       Date:  2002-04       Impact factor: 3.825

5.  von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata.

Authors:  R A Lewis; L P Gerson; K A Axelson; V M Riccardi; R P Whitford
Journal:  Ophthalmology       Date:  1984-08       Impact factor: 12.079

6.  The surgical management of childhood orbito-temporal neurofibromatosis.

Authors:  Vickie Lee; Nicola K Ragge; J Richard O Collin
Journal:  Br J Plast Surg       Date:  2003-06

7.  Orbit deformities in craniofacial neurofibromatosis type 1.

Authors:  Claude Jacquemin; Thomas M Bosley; Helena Svedberg
Journal:  AJNR Am J Neuroradiol       Date:  2003-09       Impact factor: 3.825

8.  Optic radiation involvement in optic pathway gliomas in neurofibromatosis.

Authors:  Grant T Liu; Michael C Brodsky; Peter C Phillips; Jean Belasco; Anna Janss; Jeffrey C Golden; Larissa L Bilaniuk; G Timothy Burson; Ann-Christine Duhaime; Leslie N Sutton
Journal:  Am J Ophthalmol       Date:  2004-03       Impact factor: 5.258

9.  Orbitotemporal neurofibromatosis. Clinical features and surgical management.

Authors:  Vickie Lee; Nicola K Ragge; J Richard O Collin
Journal:  Ophthalmology       Date:  2004-02       Impact factor: 12.079

10.  Orbital optic glioma in neurofibromatosis. Magnetic resonance diagnosis of perineural arachnoidal gliomatosis.

Authors:  S R Seiff; M C Brodsky; G MacDonald; B O Berg; E L Howes; W F Hoyt
Journal:  Arch Ophthalmol       Date:  1987-12
View more
  9 in total

Review 1.  Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Multidisciplinary Recommendations for Care.

Authors:  Robert A Avery; James A Katowitz; Michael J Fisher; Gena Heidary; Eva Dombi; Roger J Packer; Brigitte C Widemann
Journal:  Ophthalmology       Date:  2016-11-03       Impact factor: 12.079

2.  Lisch and the Importance of His Nodules.

Authors:  A Maharaj; V Rs Singh; S A Lalchan
Journal:  West Indian Med J       Date:  2014-09-04       Impact factor: 0.171

3.  Isolated nonpulsatile enophthalmos in neurofibromatosis: An uncommon entity.

Authors:  Swati Singh; Kaustubh Mulay; Vikas Mittal
Journal:  Indian J Ophthalmol       Date:  2017-10       Impact factor: 1.848

4.  Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas.

Authors:  Robert A Avery; Eva Dombi; Kelly A Hutcheson; Maria T Acosta; Andrea M Baldwin; William P Madigan; Andrea Gillespie; Edmond J Fitzgibbon; Roger J Packer; Brigitte C Widemann
Journal:  Am J Ophthalmol       Date:  2013-02-26       Impact factor: 5.258

5.  Differential gene methylation and expression of HOX transcription factor family in orbitofacial neurofibroma.

Authors:  Antje Arnold; Eddie Luidy Imada; M Lisa Zhang; Deepak P Edward; Luigi Marchionni; Fausto J Rodriguez
Journal:  Acta Neuropathol Commun       Date:  2020-05-04       Impact factor: 7.801

Review 6.  Pathology of eyelid tumors.

Authors:  Jacob Pe'er
Journal:  Indian J Ophthalmol       Date:  2016-03       Impact factor: 1.848

7.  Surgical correction in orbitotemporal neurofibromatosis with dystopia.

Authors:  Matthew Seung Suk Choi; Seung Hyup Choi; Jang Hyun Lee
Journal:  BMC Ophthalmol       Date:  2016-01-07       Impact factor: 2.209

8.  Solitary neurofibroma of eyelid masquerading as chalazion.

Authors:  Nancy Chen; Yung-Hsiang Hsu; Yuan-Chieh Lee
Journal:  Int Med Case Rep J       Date:  2017-05-23

9.  RNA-sequencing highlights differential regulated pathways involved in cell cycle and inflammation in orbitofacial neurofibromas.

Authors:  Eddie Luidy Imada; Diego Strianese; Deepak P Edward; Rawan alThaqib; Antionette Price; Antje Arnold; Hailah Al-Hussain; Luigi Marchionni; Fausto J Rodriguez
Journal:  Brain Pathol       Date:  2021-07-23       Impact factor: 6.508

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.